For example, NTPDase1/CD39 was shown to eliminate vascular thrombosis and inflammation (Kanthi et al., 2014; Covarrubias et al., 2016; Anyanwu et al., 2019; Yadav et al., 2019), whereas purinergic antithrombotic drugs demonstrated efficacy in lowering the likelihood of recurrent strokes and heart attacks (Burnstock, 2006). This evidence concerns the gene ENTPD1 and myocardial infarction.